Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats Attention Deficit Hyperactivity Disorder (ADHD). Sold as Catapres, Duraclon, Jenloga, Kapvay, Onyda Xr and 2 more. Every FDA application for this active ingredient: 6 branded and 54 generic.
As of Nov 15, 2026, FDA lists 60 applications for Clonidine Hydrochloride (sold as Catapres, Duraclon, Jenloga and others), first approved Sep 3, 1974, with 4 new uses approved and 0 published complete response letters.
First approved: Sep 3, 1974
Applications: 60
New uses approved: 4
Complete response letters: 0
Medicare spending, 2025: $24.3M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Clonidine HCl
Part D
$22.3M
-1%
907,402
Clonidine HCl ER
Part D
$1.9M
+40%
4,645
Onyda XR
Part D
$95K
New
41
Javadin
Part D
$0K
New
0
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
CLONIDINE 0.1 MG/DAY PATCH: $6.54 per unitGeneric · -5% in a year
CLONIDINE 0.2 MG/DAY PATCH: $8.77 per unitGeneric · -7% in a year
CLONIDINE 0.3 MG/DAY PATCH: $12.38 per unitGeneric · +6% in a year
CLONIDINE HCL 0.05 MG TABLET: $1.17 per unitGeneric · new this year
CLONIDINE HCL 0.1 MG TABLET: $0.023 per unitGeneric · -6% in a year
CLONIDINE HCL 0.2 MG TABLET: $0.034 per unitGeneric · -4% in a year
CLONIDINE HCL 0.3 MG TABLET: $0.041 per unitGeneric · 0% in a year
CLONIDINE HCL ER 0.1 MG TABLET: $0.224 per unitGeneric · -20% in a year
CLONIDINE HCL ER 0.17 MG TAB: $15.21 per unitGeneric · +4% in a year
ONYDA XR 0.1 MG/ML SUSPENSION: $13.37 per MLBrand · +31% in a year
JAVADIN 0.02 MG/ML SOLUTION: $1.53 per MLBrand · new this year
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Boehringer Ingelheim
Impax Labs
Fresenius Kabi USA
Zydus Pharms
Sun Pharm Inds Inc
Teva
Par Pharm